fda compounding semaglutide enforcement 2025 news Patients struggle as compounded GLP-1 access rapidly shrinks FDA to Restrict Ingredients Used

A back shelf position and opaque storage box protect the reconstituted vial from temperature swings and light exposure

Retatrutide is a powerful therapy that needs expert clinical management, proper patient selection, personalised dosing, careful side effect monitoring, and full lifestyle support

In the OASIS 4 trial, people taking the once-daily tablet at 25 mg lost 16.6% of their starting body weight over 64 weeks (1 year, 3 months) when they stuck to the treatment and followed healthy lifestyle guidance

Some people find that changing their injection day or time improves results

Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates